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INTRODUCTION
Carcinoid tumors originate from neuroendocrine cells
and are usually well-differentiated, low-grade malignant
neoplasms, mostly occurring in the gastrointestinal
tract.1 Primary Hepatic Carcinoid Tumor (PHCT) is a
rarity and represents only 0.3% of all neuroendocrine
tumors. Diagnosis of PHCT is challenging due to its
radiological similarity to other hepatic lesions and mild
non-specific symptomatology. Histology is the gold
standard to confirm and exclude other tumors including
hepatocellular carcinoma, cholangiocarcinoma and
metastatic lesions.2 PHCT usually follows a slow growth
and inert pattern and surgical resection is the treatment
of choice in most cases. For unresectable lesions,
transarterial chemoembolization (TACE) or long acting
somatostatin analogue can be considered.3 Early
diagnosis is associated with good long term outcome
and requires a high index of suspicion and histological
confirmation.
We are reporting two cases of a rare liver tumor from
South Asia, which is very infrequently reported from this
region.
CASE REPORT
Case 1: The patient was a 60-year gentleman who
presented with history of abdominal discomfort, nausea
and vomiting for 15 days. Abdominal examination
revealed a palpable mass in the right upper quadrant.
Biochemical parameters showed low Hb (8.5 gm/dl),
high serum total bilirubin of 2.8 mg/dl (direct 1.62,
indirect 1.18) and raised alkaline phosphatase (1062
IU). Viral serology was negative for hepatitis B and C.
Serum alpha-fetoprotein levels were normal and there
were no signs of chronic liver disease.
Diagnostic imaging included an abdominal ultrasound,
which revealed a large hypoechoic mass in the right lobe
of the liver. CT abdomen (Figure 1a) showed an
enlarged liver and a well circumscribed, hypodense
mass measuring 13 x 10 x 8 cm with homogeneous
contrast enhancement. He underwent an ultrasound
guided liver biopsy and histology (Figure 2), which
confirmed the diagnosis of a neuroendocrine tumor.
Metastatic workup including upper and lower
gastrointestinal endoscopy and CT chest were
performed, which were normal and ruled out the
possibility of a metastatic carcinoid tumor.
The patient was advised oncological consultation and
surgical resection of the tumor, which he refused and
was, therefore, discharged on palliative care. One month
later, he presented again with progressive abdominal
distension, shortness of breath and two episodes of
bleeding per rectum. Chest X-ray demonstrated bilateral
pleural effusion with basilar atelectasis. Patient was
started on broad-spectrum antibiotics and intravenous
(IV) fluids, but despite all the supportive measures, his
condition deteriorated and he developed severe urinary
tract infection and sepsis leading to his death.
Case 2: This was a 59-year male who presented with a
two-year history of central, dull, non-radiating abdominal
pain. On examination, he had right upper quadrant
tenderness and mild hepatomegaly. Abdominal
ultrasound revealed mildly enlarged liver and two well-
defined hyper-echoic lesions in segment VI of right lobe.
Biochemical results showed normal alpha-fetoprotein
level and negative hepatitis serology. CT abdomen
showed two well-defined heterogeneously enhanced
lesions with the largest one measuring 2.8 x 3.2 cm in
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segment VI of the liver (Figure 1b). The lesions showed
enhancement on early arterial phase and washout on
portal venous and delayed phase. Liver biopsy was
performed and histology confirmed the diagnosis of
carcinoma with neuroendocrine differentiation
(Figure 2).
The case was discussed in Tumor Board and patient
was advised surgical resection of the tumor, which he
refused due to financial constraints. The patient was
started on palliative care but he left against medical
advice.
DISCUSSION
Carcinoid tumors are rare, slow-growing neuroendocrine
tumors, which were previously reported mainly within the
gastrointestinal tract (GIT). Recent literature, however,
reports frequent involvement of lungs, pancreas and
reproductive system.4 Liver is usually a common site for
metastasis of GIT neuroendocrine tumor and Primary
Hepatic Carcinoids Tumors (PHCT) are extremely rare.
The exact histogenesis is not known; however, it is
hypothesized that they may arise from scattered
neuroendocrine cells in the intrahepatic biliary
epithelium or could be due to intestinal metaplasia as a
result of chronic inflammation of biliary system.5
PHCT are reported mainly in adult population (mean age
49.8 years) and are slightly more common in females
(58.5%).6 They can be clinically silent, possibly due to
spillage of neoplastic derived products into the portal
vein and subsequent degradation by the liver enzymes.
When symptomatic, patients usually present with weight
loss, abdominal pain, jaundice and a palpable mass on
examination. Classic carcinoid syndrome with skin
flushing, wheezing and diarrhea is mainly associated
with metastatic neuroendocrine tumors and may be
present in around 5% of patients PHCT.7
The diagnostic dilemma affiliated with this disease,
which was also apparent in our cases, is attributed to its
rarity, mild symptomatology and close resemblance to
other hepatic lesions (hepatocellular carcinoma,
cholangiocarcinoma, metastatic liver disease, etc.).
Imaging modalities, such as ultrasound, CT and MRI,
have a low specificity for carcinoid tumor due to similarity
with hemangioma and HCC.8 Octreoscan scintigraphy is
more specific compared to CT and MRI in detecting both
primary carcinoids and metastatic lesions, but has very
limited availability especially in remote centers.
Assertive diagnosis was made only on the basis of
immunohistochemistry, which verifies the neuro-
endocrine origin of PHCT by detecting markers such as
CgA, NSE, chromostatin, CEA and synaptophysin.4
The definitive management of PHCT is surgical
resection, which is very effective when tumor is confined
to a single lobe. A postoperative 5-year survival rate of
74% has been reported with early resection. In cases of
multilobar and non-resectable lesions, palliative
cytoreduction surgery with TACE can be effective.5 For
metastatic hepatic carcinoids, therapy with radio-
nucleotides and the somatostatin analogs can be a
reasonable option.9
Both of these cases were diagnosed very late and had a
poor outcome. This implies the importance of early
diagnosis and management of PHCT, which in itself
follows an inert course if treated timely. However, living
in a region with high prevalence of HBV and HCV,
hepatocellular carcinoma (HCC) is usually a strong initial
suspect in patients with liver tumors and must be
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Figure 1 (a): Case 1: CT scan showing a large heterogeneously enhancing
leision in the right liver lobe with filling defect right branch of portal vein
representing thrombosis. (b) (Case 2) Two, well-defined, heterogeneously
enhancing lesions are identified in segment VI of right lobe of liver. These
lesions show enhancement on early arterial phase and washout on portal
venous and delayed phase.
Figure 2: (a) Aggregates and sheets of tumour cells with pleomorphic.
(b) Tumour cells arranged around blood vessels (H&E x 20). (c) Tumor cells
showing positivity for immunohistochemical stain CK CAM5.2 (X20).
(d) Tumor cells showing positivity for immunohistochemical stain CK
AE1/AE3 (X20). (e) Tumor cells showing positivity for immunohistochemical
stain CD56 (X20).
Primary hepatic carcinoid tumor
Journal of the College of Physicians and Surgeons Pakistan 2016, Vol. 26 (3): 227-229 229
excluded via histology, since both HCC and PHCT have
completely different management. The authors also
imply on the competence of histopathologist and
availability of CD markers for diagnosis of PHCT.
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